Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.

Masood, Adeel; Wahab, Ahsan; Clifford, Tanya; Weaver, Eric J; Ehsan, Hamid; El Ayass, Walid

Masood, Adeel; Wahab, Ahsan; Clifford, Tanya; Weaver, Eric J; Ehsan, Hamid; El Ayass, Walid.

Afiliación

Masood A; Masters of Public Health in Epidemiology at the University of Alabama at Birmingham Alabama USA.
Wahab A; Tidal Health Peninsula Regional Salisbury Maryland USA.
Clifford T; Baptist Medical Center South University of Alabama at Birmingham Montgomery Alabama USA.
Weaver EJ; Tidal Health Peninsula Regional Salisbury Maryland USA.
Ehsan H; Tidal Health Peninsula Regional Salisbury Maryland USA.
El Ayass W; Levine Cancer Institute/Atrium Health Charlotte North Carolina USA.

Clin Case Rep ; 9(12): e05184, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34917381

Palabras clave

HLH; hematology/oncology; immune checkpoint inhibitors; ipilimumab; nivolumab; pembrolizumab; secondary hemophagocytic lymphohistiocytosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Clin Case Rep Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google